1.	Smoking Cessation Program in the Preadmission Clinic Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Other, Pharmaceutical / Industry Protocol IDs: 07-0585-AE, Protocol# in Pfizer: GA30517W, NCT00937508
2.	STOP Study: Effectiveness of Zyban in a Clinical Population Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 005/2008, NCT01015170
3.	The Pharmacogenetic Study , Readiness to Change , and Pharmacological Intervention for Smoking Cessation in Schizophrenia Phase: Phase IV Type: Behavioral study, Biomarker/Laboratory analysis, Prevention Status: Active Age: 16 to 65 Sponsor: Other Protocol IDs: MD-095-PP-05A, NCT00495352
4.	Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 16 to 45 Sponsor: Other Protocol IDs: P50DA016511, NCT00664755
5.	Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD) Phase: Phase IV Type: Behavioral study, Prevention Status: Active Age: 18 to 60 Sponsor: Other Protocol IDs: 2009-P-000444, NCT00907218
6.	Smoking Cessation for Veterans With Severe and Persistent Mental Illness Phase: Phase III, Phase II Type: Behavioral study, Prevention Status: Approved-not yet active Age: 18 to 75 Sponsor: Other Protocol IDs: NURA-001-09S, NCT00960375
7.	Impact of Smoking Cessation on Sleep - 5 Phase: Phase III, Phase II Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
8.	Pharmacogenetics, Emotional Reactivity and Smoking Phase: Phase III, Phase II Type: Behavioral study, Biomarker/Laboratory analysis, Prevention Status: Active Age: 18 to 65 Sponsor: NCI, Other Protocol IDs: 2003-1024, 1R01DA017073, NCT00507728
9.	Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Phase: Phase III Type: Prevention, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: KROG-4-2008-0276, 4-2008-0276, NCT00955695
10.	NicVAX/Placebo as an Aid for Smoking Cessation Phase: Phase III Type: Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: Nabi-4514, NIH grant # 1 RC2 DA028837-01, NCT00836199
11.	Evaluating a Telemedicine Smoking Cessation Program in Rural Primary Care Practices Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: NHLBI Protocol IDs: 625, HL087643-01A2, NCT00843505
12.	Yoga for Women Attempting Smoking Cessation Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: R21 AT003669-01, R21AT003669-01, NCT00492310
13.	Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: Pro00013846, NCT00894166
14.	Efficacy and Safety Study of Nicotine Mint Lozenge (2mg and 4mg) in Smoking Cessation Phase: Phase III Type: Behavioral study, Prevention Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CHN-Nicotine Mint Lozenge-002, NCT00985985
15.	Clinical Trial of Vitamin D3 to Reduce Cancer Risk in Postmenopausal Women Phase: Phase III Type: Prevention Status: Active Age: 55 and over Sponsor: NCI, Other Protocol IDs: CAPS08-15024, NCT01052051
16.	Modulation of Arachidonic Acid Metabolism by Chemopreventive Agents in Smokers Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Prevention Status: Approved-not yet active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 2009-0804, MDA09-13-01, NCT01021215
17.	Enzastaurin in Preventing Non-Small Cell Lung Cancer in Former Smokers Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 45 and over Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: MCC-14787, H6Q-MC-S009, MCC-104545, LILLY-H6Q-MC-S009A, U01-CA-101222, NCT00387816
18.	A Trial of Placebo Versus Enzastaurin for Lung Cancer Prevention in Former Smokers Phase: Phase II Type: Prevention Status: Active Age: 45 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 10723, H6Q-MC-S009, NCT00414960
19.	Green Tea Extract in Treating Current or Former Smokers With Bronchial Dysplasia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 45 to 74 Sponsor: NCI Protocol IDs: BCCA-H07-02401, H07-02401, NCT00611650
20.	Phenethyl Isothiocyanate in Preventing Lung Cancer in Smokers Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 21 to 70 Sponsor: NCI Protocol IDs: UMN-2007NT127, PEITC, NCT00691132
21.	Inositol in Preventing Lung Cancer in Current or Former Smokers With Bronchial Dysplasia Phase: Phase II Type: Biomarker/Laboratory analysis, Prevention Status: Active Age: 45 to 79 Sponsor: NCI Protocol IDs: MAYO-MAY06-8-01, MAY06-8-01, NCT00783705
22.	Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 2: Do Varenicline (Chantix) and Bupropion (Zyban) Change Alcohol Drinking? Phase: Phase II Type: Behavioral study, Prevention Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HIC0702002391, R01AA015596-01, NCT00580645
23.	Do Treatments for Smoking Cessation Affect Alcohol Drinking? Study 1: Nicotine Replacement Therapy Phase: Phase II Type: Behavioral study, Prevention Status: Active Age: 21 and over Sponsor: Other Protocol IDs: HIC0508000486, R01AA015596-01, NCT00699556
24.	Curbing Tobacco Use in Suburban and Rural Schools Phase: Phase I Type: Behavioral study, Prevention Status: Active Age: 14 to 16 Sponsor: NCI, Other Protocol IDs: 2005-0914, NCT00513097
25.	Mood Management Phone Counseling in Smoking Cessation Phase: Phase I Type: Behavioral study, Prevention Status: Active Age: 18 to 65 Sponsor: Other Protocol IDs: 1RO1DA017947, NCT00500877